Vanguard Group Inc. Has $1.03 Billion Stake in Henry Schein, Inc. (NASDAQ:HSIC)

Vanguard Group Inc. trimmed its position in shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 0.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,624,968 shares of the company’s stock after selling 9,022 shares during the quarter. Vanguard Group Inc. owned 11.53% of Henry Schein worth $1,027,654,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Palisade Capital Management LLC NJ grew its holdings in Henry Schein by 3.7% during the third quarter. Palisade Capital Management LLC NJ now owns 17,028 shares of the company’s stock worth $1,120,000 after buying an additional 601 shares in the last quarter. Pathstone Family Office LLC grew its holdings in Henry Schein by 22.4% during the third quarter. Pathstone Family Office LLC now owns 10,459 shares of the company’s stock worth $688,000 after buying an additional 1,911 shares in the last quarter. Quantamental Technologies LLC bought a new stake in Henry Schein during the third quarter worth $931,000. Marshall Wace LLP bought a new stake in Henry Schein during the third quarter worth $7,095,000. Finally, ETF Managers Group LLC grew its holdings in Henry Schein by 4.0% during the third quarter. ETF Managers Group LLC now owns 7,858 shares of the company’s stock worth $517,000 after buying an additional 303 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Philip A. Laskawy sold 6,405 shares of the stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $78.74, for a total transaction of $504,329.70. Following the sale, the director now owns 26,239 shares of the company’s stock, valued at approximately $2,066,058.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Henry Schein news, CEO Bradford C. Connett sold 6,840 shares of the firm’s stock in a transaction dated Wednesday, December 21st. The stock was sold at an average price of $80.71, for a total value of $552,056.40. Following the sale, the chief executive officer now owns 55,412 shares of the company’s stock, valued at approximately $4,472,302.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Philip A. Laskawy sold 6,405 shares of the firm’s stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $78.74, for a total value of $504,329.70. Following the completion of the sale, the director now directly owns 26,239 shares in the company, valued at approximately $2,066,058.86. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,586 shares of company stock valued at $2,294,405. Corporate insiders own 1.00% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on HSIC. Barrington Research reduced their price objective on Henry Schein from $99.00 to $92.00 and set an “outperform” rating for the company in a research note on Friday, February 17th. UBS Group upped their price objective on Henry Schein from $75.00 to $82.00 and gave the company a “neutral” rating in a research note on Tuesday, March 7th. Piper Sandler upped their price objective on Henry Schein from $85.00 to $97.00 and gave the company an “overweight” rating in a research note on Monday, February 6th. Credit Suisse Group reduced their price objective on Henry Schein from $99.00 to $97.00 and set an “outperform” rating for the company in a research note on Tuesday, February 28th. Finally, Morgan Stanley dropped their price target on Henry Schein from $70.00 to $69.00 and set an “underweight” rating on the stock in a research report on Tuesday, February 21st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $85.89.

Henry Schein Stock Up 0.7 %

Shares of NASDAQ HSIC opened at $77.56 on Tuesday. The business’s fifty day moving average price is $82.19 and its 200-day moving average price is $77.21. The stock has a market capitalization of $10.18 billion, a PE ratio of 19.94, a P/E/G ratio of 1.78 and a beta of 0.80. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.79 and a quick ratio of 0.91. Henry Schein, Inc. has a one year low of $64.75 and a one year high of $92.68.

Henry Schein (NASDAQ:HSIC – Get Rating) last issued its quarterly earnings data on Thursday, February 16th. The company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.21 by $0.14. The business had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.37 billion. Henry Schein had a return on equity of 15.79% and a net margin of 4.25%. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.07 EPS. On average, equities research analysts anticipate that Henry Schein, Inc. will post 5.33 EPS for the current year.

Henry Schein Profile

(Get Rating)

Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgicals, diagnostic tests, infection-control products and vitamins.